JAK1 and autoimmune disease: Ruxolitinib (JAK1/JAK2), Tofacitinib (JAK1/JAK3) and Ritlecitinib (JAK3 selective) were selected in the current study based on their clinical efficacies in treating lymphoma and autoimmune diseases.